In brief
In the wake of increasing public dissatisfaction with generic medications, Chinese healthcare officials face scrutiny over drug efficacy amid a strained healthcare system. Discussions about substandard generics have led to public outrage and demands for reforms to ensure safe and effective medicines.
Public dissatisfaction has surged in China as new reports emerge about the increasing ineffectiveness of generic drugs widely distributed in public hospitals. An ongoing debate about the country’s drug procurement system, which emphasizes low-cost generics over brand-name pharmaceuticals, has led to a rare acknowledgment from government officials concerned about the long-term implications for public health.The controversy ignited in December following the announcement of nearly 200 domestic companies awarded contracts to supply medicines to state hospitals, primarily generic manufacturers. The situation gained momentum in January when Dr. Zheng Minhua, a Shanghai hospital department director, publicly shared his troubling experiences with the current system, listing instances of ineffective antibiotics, laxatives, and other medications. He warned that the focus on low-cost generics often compromises safety and effectiveness, causing widespread alarm among patients.Despite authorities claiming public fears are based on perception rather than reality, many citizens are not convinced. Personal anecdotes flood social media platforms, with individuals recounting ineffective treatment experiences and questioning the quality of generic drugs. One Weibo user articulated their frustration, stating that they turned to alternative methods, such as consuming coffee to induce bowel movement after using ineffective laxatives.The backlash stems from China’s significant push to support its domestic generic drug market, which saves the state billions but raises concerns about potential quality issues. The controversial procurement system, implemented in 2018, centralizes purchasing for approximately 70% of hospital drug requirements, leading many manufacturers to aggressively bid low without ensuring proper quality control. Reports of generics so cheap that a single aspirin costs less than one cent have raised serious questions about whether such products are even safe for consumption.Growing anxiety over drug quality has sparked a demand for better access to imported drugs, perceived as being of higher quality. The lack of brand-name alternatives in public healthcare exacerbates frustrations, leading to a growing sentiment among patients that they should be allowed to purchase the medications they trust.Amidst this crisis, the challenges facing China’s healthcare structure are magnified by an ageing population that has driven health expenditures to nearly 20-fold increase over 20 years. The fiscal strain has made it clear that the procurement system needs reform to ensure that affordability does not come at the expense of safety and efficacy.As the state begins to respond, experts indicate that improvements in drug evaluation standards are critical to regain public trust. With the healthcare system under intense scrutiny, the balancing act of providing affordable care while maintaining quality has never been more urgent for China’s leaders. The ongoing backlash serves as a call to action for regulators to reevaluate the procurement process and prioritize patient safety in their desperate efforts to sustain public health.
